Krilogy Financial’s Allogene Therapeutics ALLO Stock Holding History

Krilogy Financial’s Portfolio ALLO Stock Details ALLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-16,780	Closed	-$39.8K	–	1078
2026 Q1	$39.8K	Buy	+16,780	New	+$33.6K	﹤0.01%	955

Other funds holding ALLO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Pfizer New York $170M AUM 191.09% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Krilogy Financial's ALLO Position: Q2 2026 in Review

Krilogy Financial sold out of Allogene Therapeutics (ALLO) in Q2 2026, closing a stake of 16,780 shares — an estimated $39.8K sold.

Krilogy Financial first reported a position in ALLO in Q1 2026 and held it in 1 quarter. The position peaked at $39.8K in Q1 2026. 210 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

Krilogy Financial reported no remaining Allogene Therapeutics position as of Q2 2026 after selling out during the quarter.
Krilogy Financial sold 16,780 Allogene Therapeutics shares in Q2 2026, an estimated $39.8K.
Krilogy Financial first reported a position in Allogene Therapeutics in Q1 2026 and held it in 1 quarter.
Krilogy Financial's Allogene Therapeutics position peaked at $39.8K in Q1 2026.
210 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on Krilogy Financial's 13F filing for Q2 2026, filed 27 Jul 2026.